Ultra-hypofractionated Radiation in Prostate Cancer

Early Stage Prostate Cancer Clinical Trial

Official title:

Pilot Trial of Ultra-hypofractionated Radiation in Early Prostate Cancer

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03486821
• Other study ID #: IIT-2017-PROS-UltraHypoFracRT
• Status: Active, not recruiting
• Phase: N/A
• Start date: March 22, 2018
• Est. completion date: March 1, 2026

Study information

• Verified date: April 2023
• Source: University of Kansas Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to demonstrate that ultra-hypofractionation of prostate cancer does not increase urinary toxicity as defined by the EPIC-26 GU domain patient reported outcome.

Description:

This is a pilot clinical trial looking at 2 fraction SBRT radiation therapy as an alternative to standard of care. Data does not yet exist for the safety and efficacy of this regimen.

However, the feasibility of ultra-short radiation therapy treatments has already been demonstrated in an analogous treatment using high-dose rate (HDR) brachytherapy. HDR brachytherapy has been adopted at high volume cancers centers as a standard treatment for prostate cancer. Typical doses have been 26 - 27 Gy over 2 fractions (13 or 13.5 Gy per fraction). Overall, toxicity and efficacy of HDR brachytherapy have compared favorably to other treatment modalities.

Dosimetric planning models between SBRT and HDR brachytherapy suggest minor differences. HDR brachytherapy was able to achieve higher intraprostatic maximum doses and lower rectal doses, but target volume coverage and urethral dose was not significantly different. These data suggest that reducing SBRT treatments from 5 fractions to 2 fractions may be feasible, efficacious and tolerable.

Eligible patients include all patients who are otherwise eligible for standard 5 fraction SBRT prostate. Study population will be low and intermediate patients with good urinary function (as defined by small prostate volume and low IPSS score). SBRT treatment will be delivered to the prostate to 12.5 Gy x 2 fractions.

Hormonal therapy is permitted on this study. Permitted agents include: leuprolide (Lupron/Eligard), biclutamide (Casodex), and degarelix (Firmagon).

Rectal sparing with hydrogel spacer (SpaceOAR) will be encouraged.

All patients will be enrolled with interim safety analyses after every occurrence of a grade 3 acute or late toxicity. Interval safety analysis will also be performed for recurrence and decrease in EPIC GU domain quality of life. Biospecimen and financial toxicity data will also be collected.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 13
• Est. completion date: March 1, 2026
• Est. primary completion date: March 1, 2025
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Ability of participant to sign a written informed consent.

• Diagnosed with prostate cancer, T1-T2bN0M0 GS6-7, PSA < 20

• IPSS score < 15 (and < 10 if on medication for benign prostatic hypertrophy such as tamsulosin) at time of enrollment (Appendix 21.4)

• Prostate volume (by US, CT or MRI measurement) < 50 cc at time of enrollment

• Androgen deprivation therapy based on clinician judgment is permitted on study

• Life expectancy > 10 years based on clinician's judgment

• No other active malignancy

• Age = 18 years

• Performance Status Eastern Cooperative Oncology Group (ECOG) 0-1 (Appendix 21.5).

• Other study-specific criteria:

• Men of child-bearing potential must not donate sperm while on this study and for 90 days after their last study treatment.

NOTE: Acceptable forms of birth control are listed below:

• One Barrier method (cervical cap with spermicide plus male condom; diaphragm with spermicide plus male condom) PLUS

• Hormonal method (oral contraceptives, implants, or injections) or an intrauterine device (e.g., Copper-T).

Exclusion Criteria:

• Current or anticipated use of other investigational agents while participating in this study.

• Psychiatric illness/social situations that would limit compliance with study requirements

• Prior pelvic radiation therapy

• Prior prostatectomy

• Inflammatory bowel disease or connective tissue disease requiring medical management

Related Conditions & MeSH terms

• Early Stage Prostate Cancer
• Prostatic Neoplasms

Intervention

Radiation:
• Hypofractionated Radiation
All patients on this study will receive the same type of therapy, 2 treatment hypofractionated radiation therapy.

Locations

Country	Name	City	State
United States	University of Kansas Medical Center/ Cancer Center	Kansas City	Kansas

Sponsors (1)

Lead Sponsor	Collaborator
University of Kansas Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Toxicity Rates	Patient reported urinary function, as defined by the EPIC-26 GU domain patient reported outcome for prostate cancer patients	up to 5 year post radiation
Secondary	Biochemical Control Rate	Biochemical freedom from progression as defined by ASTRO Phoenix criteria at 3 years	1 month post-Radiation Therapy (RT), every 3 months- post RT for the first year and then every 6 months post RT for the next 4 years
Secondary	Radiation Therapy Oncology Group (RTOG) Late Toxicity Rate	Rate of Grade 3+ gastrointestinal (GI) or genitourinary (GU) late toxicity at 3 years as defined by RTOG late toxicity scored on a 1 to 4 scale with a higher value representing a worse outcome.	3 year
Secondary	RTOG Acute Toxicity Rate	Rate of Grade 2+ GI or GU acute toxicity within 90 days of treatment as defined by RTOG acute toxicity scored on a 1 to 4 scale with a higher value representing a worse outcome.	90 days
Secondary	Oxidative stress as a predictor of toxicity	exploring the oxidative stress markers of the patient to use as a predictor of acute and late toxicty	1 month post-RT, every 3 months- post RT for the first year and then every 6 months post RT for the next 4 years
Secondary	Financial Toxicity Measurement	Determined by evaluation of patient completion of questionnaire	3 months, 6 months, and 12 month visits only